370 related articles for article (PubMed ID: 12057039)
1. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Hirsch FR; Helfrich B; Franklin WA; Varella-Garcia M; Chan DC; Bunn PA
Clin Breast Cancer; 2002 May; 3 Suppl 1():12-6. PubMed ID: 12057039
[TBL] [Abstract][Full Text] [Related]
2. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Bunn PA; Helfrich B; Soriano AF; Franklin WA; Varella-Garcia M; Hirsch FR; Baron A; Zeng C; Chan DC
Clin Cancer Res; 2001 Oct; 7(10):3239-50. PubMed ID: 11595720
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Konecny GE; Pegram MD
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):32-6. PubMed ID: 15685824
[TBL] [Abstract][Full Text] [Related]
4. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Pegram MD; Konecny GE; O'Callaghan C; Beryt M; Pietras R; Slamon DJ
J Natl Cancer Inst; 2004 May; 96(10):739-49. PubMed ID: 15150302
[TBL] [Abstract][Full Text] [Related]
5. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
Gatzemeier U; Groth G; Butts C; Van Zandwijk N; Shepherd F; Ardizzoni A; Barton C; Ghahramani P; Hirsh V
Ann Oncol; 2004 Jan; 15(1):19-27. PubMed ID: 14679114
[TBL] [Abstract][Full Text] [Related]
7. The role of HER2/neu expression and trastuzumab in non-small cell lung cancer.
Hirsch FR; Langer CJ
Semin Oncol; 2004 Feb; 31(1 Suppl 1):75-82. PubMed ID: 14981584
[TBL] [Abstract][Full Text] [Related]
8. HER2/neu expression in malignant lung tumors.
Hirsch FR; Franklin WA; Veve R; Varella-Garcia M; Bunn PA
Semin Oncol; 2002 Feb; 29(1 Suppl 4):51-8. PubMed ID: 11894014
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu.
Stein S; DeMichele A; Domchek S; Fox K
Clin Breast Cancer; 2004 Jan; 4 Suppl 3():S117-20. PubMed ID: 14754469
[TBL] [Abstract][Full Text] [Related]
10. Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Hanada M; Noguchi T; Yamaoka T
Cancer Sci; 2007 Mar; 98(3):447-54. PubMed ID: 17214744
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
Lara PN; Laptalo L; Longmate J; Lau DH; Gandour-Edwards R; Gumerlock PH; Doroshow JH; Gandara DR;
Clin Lung Cancer; 2004 Jan; 5(4):231-6. PubMed ID: 14967075
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
Zinner RG; Glisson BS; Fossella FV; Pisters KM; Kies MS; Lee PM; Massarelli E; Sabloff B; Fritsche HA; Ro JY; Ordonez NG; Tran HT; Yang Y; Smith TL; Mass RD; Herbst RS
Lung Cancer; 2004 Apr; 44(1):99-110. PubMed ID: 15013588
[TBL] [Abstract][Full Text] [Related]
13. In vitro comparative evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere) in HER2-expressing human breast cancer cell lines.
Merlin JL; Barberi-Heyob M; Bachmann N
Ann Oncol; 2002 Nov; 13(11):1743-8. PubMed ID: 12419746
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and trastuzumab in metastatic breast cancer.
O'shaughnessy J
Semin Oncol; 2003 Apr; 30(2 Suppl 3):22-6. PubMed ID: 12722022
[TBL] [Abstract][Full Text] [Related]
15. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.
Paudyal P; Paudyal B; Hanaoka H; Oriuchi N; Iida Y; Yoshioka H; Tominaga H; Watanabe S; Watanabe S; Ishioka NS; Endo K
Cancer Sci; 2010 Apr; 101(4):1045-50. PubMed ID: 20219072
[TBL] [Abstract][Full Text] [Related]
16. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results.
Zinner RG; Kim J; Herbst RS
Lung Cancer; 2002 Jul; 37(1):17-27. PubMed ID: 12057863
[TBL] [Abstract][Full Text] [Related]
17. The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer.
Hahn T; Bradley-Dunlop DJ; Hurley LH; Von-Hoff D; Gately S; Mary DL; Lu H; Penichet ML; Besselsen DG; Cole BB; Meeuwsen T; Walker E; Akporiaye ET
BMC Cancer; 2011 Nov; 11():471. PubMed ID: 22044845
[TBL] [Abstract][Full Text] [Related]
18. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
19. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression.
Menderes G; Bonazzoli E; Bellone S; Altwerger G; Black JD; Dugan K; Pettinella F; Masserdotti A; Riccio F; Bianchi A; Zammataro L; de Haydu C; Buza N; Hui P; Wong S; Huang GS; Litkouhi B; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Oct; 147(1):145-152. PubMed ID: 28705408
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.
Loesch D; Asmar L; McIntyre K; Doane L; Monticelli M; Paul D; Vukelja S; Orlando M; Vaughn LG; Zhan F; Boehm KA; O'Shaughnessy JA
Clin Breast Cancer; 2008 Apr; 8(2):178-86. PubMed ID: 18621615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
